The Research advance in systemic lupus erythematosus co-infection.

doi:10.7504/ek2015010603

Abstract

Abstract:

Abstract： The treatment of SLE becomes standard in recent year. Serious complications caused by infection become the leading cause of death in SLE， more than renal involvement and lupus encephalopathy. SLE co-infection mainly connects with the defects in humoral immunity and cellular immunity. And also connect with the disease activity， the dose of hormone and immune inhibitor.

Key words: systemic lupus erythematosus, infection, antinuclear antibody, Epstein-Barr virus

摘要：

近年来，随着系统性红斑狼疮（SLE）治疗不断规范化，感染及其引起的严重并发症已超过肾脏受累及狼疮脑病成为SLE患者死亡的首要原因。SLE合并感染主要与患者体液免疫、细胞免疫缺陷以及SLE疾病活动性、激素与免疫抑制剂应用有关。

关键词: 系统性红斑狼疮, 感染, 抗核抗体, EB病毒

CLC Number:

Ｒ72

SUN Guang-chao，ZENG Hua-song.. The Research advance in systemic lupus erythematosus co-infection.[J]. Acta Metallurgica Sinica, DOI: 10.7504/ek2015010603.

孙广超，曾华松. 系统性红斑狼疮合并感染研究进展[J]. 中国实用儿科杂志, DOI: 10.7504/ek2015010603.

References

[1］费允云，甘凤英，侯勇. 近25年系统性红斑狼疮的死因构成回顾性研究［J］. 中华风湿病学杂志，2012，16（9）：596-600.

[2］ Mok M，Wong S，Chan T，et al. Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus［J］. Rheumatology，2007，46（2）：280.

[3］ Chen H，Tsai WP，Leu HS，et al. Invasive fungal infection in systemic lupus erythematosus： an analysis of 15 cases and a literaturreview［J］. Rheumatology，2007，46（3）：539.

[4］ Draborg AH，Duus K，Houen G. Epstein-Barr virus in systemicautoimmune diseases［J］. Clin Dev Immunol，2013，2013：535738.

[5］ Barzilai O，Sherer Y，Ram M，et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases：are they truly notorious?Apreliminary report［J］. Ann N Y AcadSci，2007，1108：567-577.

[6］ Mcclain MT，Poole BD，Bruner BF，et al. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus［J］. Arthritis Rheum，2006，54：360-368.

[7］ Harley JB，James JA. Epstein-Barr virus infection induces lupusautoimmunity［J］. Bull NYU HospJt Dis，2006，64：45-50.

[8］李毅. EB 病毒感染与系统性红斑狼疮患者外周血中B淋巴细胞异常活化的相关性研究［J］. 中华风湿病学杂志，2009，13（6）：394-396.

[9］王丽芹，王吉波，潘琳，等. EB病毒潜伏期膜蛋白1诱发系统性红斑狼疮可能机制的探讨［J］. 中华风湿病学杂志，2011，15（10）：707-709.

[10］ Quan TE，Roman RM，Rudenga BJ，et al. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells［J］. Arthritis Rheum，2010，62：1693.

[11］ James JA，Robertson JM. Lupus and Epstein-Barr［J］. Curr Opin Rheumatol，2012，24：383-388.

[12］ Larsen M，Sauce D，Deback C，et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus［J］. PLoS Pathog，2011，7：e1002328.

[13］ Tattevin P， Le Tulzo Y， Minjolle S，et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis：surveillance study［J］. J Clin Microbiol， 2006，44（5）：1873-1874.

[14］张小立，冯修高. EB 病毒近期感染与系统性红斑狼疮的关联性研究［J］. 中华临床医师杂志，2013，7（14）：6349-6354.

[15］麦慈光，张道友，叶任高. 90例系统性红斑狼疮患者死亡原因分析［J］. 中华肾脏病杂志，1998，14（2）：114-116.

[16］胡继荣，李德宪. 系统性红斑狼疮死亡相关因素的分析［J］. 岭南皮肤性病科杂志，2004，11（4）：325-326.

[17］陈晓. 5l例系统性红斑狼疮合并真菌感染临床分析［D］. 北京：中国协和医科大学，2006.

[18］ Jimper AH，Knox Ks. An official American Thorack Society statement：treatment of fungal infections in adult pulmonary and critical care patients［J］. Am J RespirCrit care Med，2011，183（1）：96-128.

[19］ Szeto CC，Kwan BC，Lai FM，et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis［J］. Rheumatology（Oxford），2008，47（11）：1678-1681.

[20］ Chen HS，Tsai WP，Leu HS，et al. Invasive fungal infection in systemic lupus erythematosus：an analysis of 15 cases and a literature review［J］. Rheumatology，2007，46（3）：539-544.

[21］吴晓静，陈楠. 系统性红斑狼疮并发感染的危险因素临床特点及早期诊断［J］. 中国实用内科杂志，2010，30（2）：154-156.

[22］ Ng W，Chu C，Yuen K，et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus［J］. QJM，2006，99（1）：37.

[23］蒋媛，赵岳，魏蔚. 系统性红斑狼疮患者合并感染临床特点分析［J］. 天津医科大学学报，2010，16（2）：295-297.

[24］ Juarez M，Misischia R，Alarcon GS. Infections in systemic connective tissue diseases：systemic lupus erythematosus，scleroderma，and polymyositis/dermatomyositis［J］. Rheum Dis ClinNorth Am，2003，29（1）：163-184.

[25］李志军，王翠兰，范晓云，等. 系统性红斑狼疮并发细菌及真菌感染的临床研究［J］. 中华风湿病学杂志，2000，4（3）：165-168.

[26］ Lunch JP，Martinez FJ. Pulmonary infection to match for transplant recipient［J］. J Respir Dis，1993，14：528.

[27］ Kim HA，Yoo CD，Baek HJ，et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patientpopulation［J］. Clin Exp Rheumatol，1998，16（1）：9-13 .

[28］ Sayarlioglu M. Tuberculosis in Turkish patients with systemiclupus erythematosus：increased frequency of extrapulmonarylocalization［J］. Lupus，2004，13（4）：274-278.

[29］ Mok MY，Lo Y，Chan TM，et a1. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during eorticosteroidtherapy［J］. J Rheumatol，2005，32：609-615.

[30］ Falagas ME，Voidonikola PT，Angelousi AG. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glueocorticosteroids and the preventive role ofisoniasid：a review of the available evidence［J］. Int J Antimierob Agents，2007，30：477-486.

[31］ Plakke MJ，Jalota L，Lloyd BJ. Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy：a question of prophylaxis［J］. BMJ Case Rep，2013. pii:bcr2012007912.doi:10.1136/bcr-20120007912.

[32］ Mansharamani NG，Balachandran D，Vemovsky I，et al. Peripheral blood CD4+T—lymphocyte counts during Pneumocystis carinii pneumonia in immanocompromised patients without HIV infection［J］. Chest，2000，118：712-720.

[33］ Vogawa J，Harigai M，Nagasaka K，et a1. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium-or high dose corticosteroid therapy［J］. Mod Rheumat，2005，15：91-96.

[34］贺彬，祝益民. 降钙素原在小儿脓毒症中的应用［J］. 中国小儿急救医学，2013，20（3）：324-326.

[35］姚冬云，霍河水. 降钙素原用于系统性红斑狼疮活动和细菌性感染快速鉴别［J］. 中华临床免疫和变态反应杂志，2014，221：227.

[36］常淑婷，李贵南，吴运芹，等. 降钙素及超敏C反应蛋白在新生儿败血症诊断中的价值［J］. 中国小儿急救医学，2013，20（4）：411-413.

[37］尤海燕，裘影影，吴玲，等. CD64指数在鉴别系统性红斑狼疮继发感染和病情活动中的意义［J］. 江苏医药，2014，40（1）：53-55.

[38］ Zeevi A，Lunz J. CylexImmuKnow cell function assay［J］. Methods Mol Biol，2013，1034：343-351.

[39］ Bhorade SM，Janata K，Vigneswaran WT，et al. CylexImmuKnow assay levels are lower in lung transplant recipients with infection［J］. J Heart Lung Transplant，2008，2008：990-994.

[1]	ZHANG Li-na，CAO Ling. Research progress in general situation of coronavirus infection [J]. CJPP, 2021, 36(6): 469-473.
[2]	LIU Li-pin*，YING Wen-jing，SUN Bi-jun，et al. Analysis of clinical characteristics of rotavirus infection in children with severe combined immunodeficiency disease　 [J]. CJPP, 2021, 36(5): 360-363.
[3]	XU Li，HE Sheng-nan，ZHANG Yu，et al. Clinical study of juvenile rheumatic disease-associated macrophage activation syndrome：A retrospective study from a single center [J]. CJPP, 2021, 36(4): 285-291.
[4]	WANG Xiang-ying，WU Jian-qiang，LU Mei-ping. Analysis of hematological involvement and immunological features of 121 cases of juvenile systemic lupus erythematosus [J]. CJPP, 2021, 36(4): 292-294.
[5]	JIANG Xin-hui, SHAO Xiao- shan. Advances in chronic disease management and Treatment of cSLE and LN [J]. Chinese Journal of Practical Pediatrics, 2021, 36(11): 842-848.
[6]	Multi-center Research Collaboration Group, Pediatric Allergy Immunology Rheumatology Branchthe Asia-Pacific Association of Medicine and Bio-Immunology（PAIRB-APAMBI）, Editorial Committee of Chinese Journal of Practical Pediatrics. Efficacy and safety analysis of belimumab for 28 weeks in real-world Chinese children with systemic lupus erythematosus：A retrospective multicenter pilot study [J]. Chinese Journal of Practical Pediatrics, 2021, 36(11): 858-868.
[7]	TANG Xiao-yan，LI Ji，GOU Li-juan，et al. Intestinal pseudo-obstruction in children with systemic lupus erythematosus：A clinical study of 8 cases [J]. CJPP, 2021, 36(1): 38-41.
[8]	LU Lin，LU Mei-ping. Research progress in systemic lupus erythematosus and regulatory T cells in children [J]. CJPP, 2020, 35(9): 741-744.
[9]	ZHANG Yu，TANG Xue-mei，WANG Li，et al. Clinical characteristics of thirty male childhood-onset systemic lupus erythematosus [J]. CJPP, 2020, 35(7): 547-551.
[10]	YIN Rong*，WANG Ting，CHEN Zheng-rong，et al. . Influenza surveillance and analysis of hospitalized children with respiratory tract infection in Children’s Hospital of Soochow University from 2016 to 2019：A report of 742 cases [J]. CJPP, 2020, 35(5): 359-363.
[11]	SONG Hong-mei. Interpretation of international guidelines for diagnosis and treatment of rheumatism in children（Ⅰ）：Interpretation of the EULAR/ACR classification criteria of systemic lupus erythematosus [J]. CJPP, 2020, 35(4): 249-252.
[12]	WEI Qi-jiao，WANG Wei，WANG Chang-yan，et al. Clinical features and gene analysis of Mendelian susceptibility to mycobacterial disease due to mutations in IL-12RB1 in two children [J]. CJPP, 2020, 35(4): 307-310.
[13]	CHEN Li-na*， LIU Han-min. Rational administration of medicine for recurrent respiratory tract infections in children [J]. CJPP, 2020, 35(3): 202-206.
[14]	Rheumatic Immunology Group of Pediatric Branch of Chinese Medical Doctor Association，China Children’s Immunity and Health Alliance，Editorial Committee of Chinese Journal of Practical Pediatrics. Expert consensus on the diagnosis and treatment of macrophage activation syndrome related to childhood rheumatism（Ⅲ）— systemic lupus erythematosus [J]. CJPP, 2020, 35(11): 834-838.
[15]	WU Ya-bin，DENG Wen-hua. Application progress of modern pediatric respiratory intervention techniques in pathogenic detection methods of pulmonary infectious diseases [J]. CJPP, 2020, 35(10): 786-791.